Search

Displaying results 2531 - 2540 of 4859 in total
  1. Drug

    Alfimeprase

    go.drugbank.com/drugs/DB04919
    Investigational

    It is a small protein that contains 203 residues (Randolph et al. 1992). Alfimeprase is being developed by Nuvelo.

  2. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

  3. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    Broad use of simeprevir occurred when it was used in combination with a newer drug, [DB08934]. … It is shown to display synergistic effects with interferon-α and HCV NS5B inhibitor, and additive effects with ribavirin in HCV replicon cells [A19629].

  4. Drug

    Trimetrexate

    go.drugbank.com/drugs/DB01157
    Approved

    It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.

  5. Drug

    Mebanazine

    go.drugbank.com/drugs/DB09248
    ApprovedWithdrawn

    It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.

  6. Drug

    4-(Isopropylamino)diphenylamine

    go.drugbank.com/drugs/DB14195
    Approved

    It is also a known allergen. Sensitivity to this compound may be identified with a clinical patch test.

  7. Drug

    CX-046684

    go.drugbank.com/drugs/DB19414
    Approved

    It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.[L40074]

  8. Drug

    Benznidazole

    go.drugbank.com/drugs/DB11989
    ApprovedInvestigational

    [L939] It is the first treatment made available in the United States for Chagas disease.

  9. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    It is being developed by Evotec Inc.

  10. Drug

    Cilomilast

    go.drugbank.com/drugs/DB03849
    Investigational

    It is orally active and acts as a selective Phosphodiesterase-4 inhibitor. … Following four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile.